BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.
Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 11 Alerts
On the day this news was published, BBIO gained 1.48%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.2% during that session. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $193M to the company's valuation, bringing the market cap to $13.26B at that time. Trading volume was very high at 3.3x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hypocalcemia type 1 (ADH1) CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Members of management will host a conference call to discuss the data at 8:00 a.m. ET the same day.
To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) release ADH1 CALIBRATE Phase 3 topline results?
What time is the BridgeBio (BBIO) conference call to discuss ADH1 CALIBRATE results?
Where can investors watch the BridgeBio (BBIO) webcast for the ADH1 CALIBRATE results?
How long will the replay of BridgeBio (BBIO) ADH1 CALIBRATE webcast remain available?
What is the ADH1 CALIBRATE study that BridgeBio (BBIO) is reporting on?
Will BridgeBio (BBIO) provide detailed data during the October 28, 2025 call?
